Introducing the NEW AAP Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents Friday, November 22, 2019 1:00 - 2:00 pm EST We invite
Introducing the NEW AAP Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of
Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents
Friday, November 22, 2019
1:00 – 2:00 pm EST
We invite you to join us on Friday, November 22, at 1:00 pm EST when Mark L. Wolraich, MD, FAAP and Joseph F. Hagan, Jr., MD, FAAP discuss the new American Academy of Pediatrics (AAP) Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. The objectives of this webinar include:
- Review the 2019 ADHD clinical practice guideline revision and its Key Action Statements.
- Describe the clinical care algorithm for primary care management.
- Assess existing barriers to care—do they provide opportunities?
To view the webinar on Friday, November 22, please click here or use the following url: https://event.webcasts.com/starthere.jsp?ei=1270510&tp_key=f429e2eebb
Mark L. Wolraich, MD, FAAP is the CMRI/Shaun Walters Emeritus Professor of Pediatrics, former Chief of the Section on Developmental and Behavioral Pediatrics, and the former Director of the Child Study Center at the University of Oklahoma Health Sciences Center.
He has been active in both the AAP and the Society for Developmental and Behavioral Pediatrics where he is a past president. He is an inductee in the Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) Hall of Fame.
Dr. Wolraich is the chairperson of the subcommittee that revised the AAP guidelines for the diagnosis, evaluation, and treatment of ADHD in children and adolescents.
Joseph F. Hagan, Jr., MD, FAAP is a clinical professor of pediatrics at The Robert Larner, MD College of Medicine at the University of Vermont and UVM Children’s Hospital. He is co-editor of Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents (3rd and 4th editions), the standard of preventive care for infants, children, adolescents, and young adults.
Dr. Hagan served as AAP Vermont Chapter Vice President and President. He chaired the Committee on Psychosocial Aspects of Child and Family Health and is a regular reviewer for Pediatrics. He also chaired the AAP Task Force on Terrorism and the Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure Workgroup. Dr. Hagan is the vice chairperson of the subcommittee that revised the AAP guidelines for the diagnosis, evaluation, and treatment of ADHD in children and adolescents.
His commitment to the care of vulnerable children led Dr. Hagan to chair the Citizen’s Advisory Board for the Vermont Department for Children and Families for almost 20 years. He has consulted for the Commissioner on complex child protection cases and is a consulting physician at the UVM Children’s Hospital ChildSafe Clinic.
An experienced advocate on community, state, and federal levels, Dr. Hagan served on the legislative committee that created Vermont’s Family Court. He has testified on behalf of the AAP before US Senate Committees regarding WIC and the ACA and often testified before the Vermont Legislature. He has wide media experience, has published extensively, presented nationally and internationally, and received numerous awards recognizing his work.
Dr. Hagan practices primary care pediatrics in Burlington, Vermont.
(Friday) 10:00 am - 11:00 am PST